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Background: Many lung carcinogens activate mitogen activated protein kinase (MAPK) pathways and DNA
methyltransferases (DNMTs) are under investigation as therapeutic targets for lung cancer. Our goal is to determine
whether C10 type II alveolar epithelial cells are a sensitive model to investigate ERK-dependent transformation and
DNMT expression patterns in experimental lung cancer.
Findings: Ectopic expression of an extracellular signal regulated kinase (ERK)-green fluorescent protein (ERK1-GFP)
induces acquisition of growth in soft agar that is selectively associated with latent effects on the expression of DNA
methyl transferases (DNMT1 and 3b), xeroderma pigmentosum complementation group A (XPA), DNA-dependent
protein kinase catalytic subunit (DNA-PKcs), increased phosphatase activity and enhanced sensitivity to 5-azacytidine
(5-azaC)-mediated toxicity, relative to controls.
Conclusions: Ectopic expression of ERK alone is sufficient to promote phenotypic conversion of C10 cells associated
with altered DNMT expression patterns and sensitivity to DNMT inhibitor. This model may have applications for
predicting sensitivity to DNMT inhibitors.
Keywords: Epigenetics, ERK, DNMTFindings
Many lung carcinogens activate the extracellular signal
regulated kinase (ERK) [1] and in some model systems
constitutive overexpression of ERK can induce
transformation [2-6]. However, it is unclear whether ERK
alone can modulate cell transformation responses in lung
type II alveolar epithelial cells. In addition, cell
transformation induced by ERK overexpression does not
correlate with ERK activity [7], suggesting an important
role for secondary regulatory events. Murine C10 type II
alveolar epithelial cells have been used as an in vitro
model to investigate molecular determinants of lung cell
physiology and pathophysiology [8-11]. C10 type II
alveolar epithelial cells are a non-tumorigenic cell line
derived from normal BALB/c mouse lung tissue and do
not contain native Ras mutations [12,13]. Type II
features include the presence of lamellar bodies, the
biosynthesis of surfactant, proliferation that is contact* Correspondence: Thomas.Weber@pnnl.gov
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distribution, and reproduction in any mediuminhibited and anchorage-dependent growth [14]. Here
we ectopically expressed an ERK1-GFP chimera in C10
cells using retroviral technology as previously described
[15] and asked whether ectopic ERK expression induced
phenotypic conversion. Thus, our use of the terms
“transformation or phenotypic conversion” are
constrained to observable changes in cell behavior linked
to carcinogenesis in vitro, such as loss of cell density-
dependent growth arrest, anchorage-independent growth
and morphological changes associated with an epithelial
to mesenchymal transition. ERK1-GFP protein expres-
sion was confirmed by Western blot (Figure 1, panel A
bottom). The phosphorylation of both ERK1-GFP and
endogenous ERKs was increased in response to growth
factor treatment (10% FBS; 10 min), relative to respective
quiescent controls (Figure 1, panel A top). ERK1-GFP
translocated to the nuclear compartment following
growth factor stimulation (Figure 1, panel B), consistent
with nuclear translocation of ERK upon activation [16].
ERK is exported from the nucleus by the chromosome
region maintenance protein 1 (CRM1) exporter [17] andentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Panel A: Expression of ERK1-GFP chimera was confirmed by Western blot analysis (bottom). Phosphorylation of both ERK1-GFP
and endogenous ERKs is increase by growth factor stimulation (FBS), relative to quiescent controls (top). Panel B: Epifluorescent microscopy
confirmed ERK1-GFP nuclear translocation following stimulation with FBS, relative to unstimulated ERK1-GFP cells. Blocking nuclear export with
leptomycin B (30 min treatment) resulted in retention of ERK1-GFP in the nucleus as expected. Similar results were observed in two independent
experiments. Methods for retroviral expression of ERK1-GFP can be found in [15].
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resulted in nuclear retention of ERK1-GFP. Therefore,
ERK1-GFP displays expected regulatory patterns in C10
cells.
ERK1-GFP transduced cells exhibit a morphological
change upon prolonged passaging (Figure 2A, compare
early and late passage cells) which often accompanies cellFigure 2 Phenotypic conversion of C10 cells induced by ERK1-GFP. Pa
relative to early passage ERK1-GFP cells and vector controls. Panel B: The p
cell contact at confluence, while proliferation of early passage ERK1-GFP ce
different from vector control. Values represent the mean± se (n = 3). Similar
Late passage cells exhibit a qualitative change in their capacity to grow in
growth responses. Methods for the soft agar assay can be found in [20]. Simtransformation in vitro [18]. Total cell number was
increased by approximately 11 fold in 5 day postconflu-
ent cultures of late passage ERK1-GFP cells, relative to
postconfluent vector control or early passage ERK1-GFP
cells (Figure 2B), indicating loss of growth inhibition by
cell-cell contact. Late passage ERK1-GFP cells grow in
soft agar, while vector controls do not show significantnel A: Late passage ERK1-GFP cells exhibit rounded morphology,
roliferation of late passage ERK1-GFP cells (L) is not inhibited by cell-
lls (E) and vector controls (V) are contact inhibited. *Significantly
results were observed in three independent experiments. Panel C:
soft agar, while vector controls show marginal anchorage-independent
ilar results were observed in two independent experiments.
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defined as previously described [19]. Collectively, late
passage ERK1-GFP cells display multiple phenotypic
alterations that suggest they have transformed to a
malignant state.
ERK can regulate DNMT expression [21,22] which
could impact epigenetic programming. Altered epigen-
etic programming is an attractive candidate in carcino-
genesis because alterations in methylation of DNA are
heritable and can lead to transcriptional dysregulation
linked to neoplastic cellular changes [23]. Upon examin-
ation of DNMT expression patterns in our model, we
observed a marked increase in DNMT1 and 3b isoforms
in late passage ERK1-GFP cells, relative to early passage
cells and vector controls (Figure 3A). DNMT3a was not
detected by Western blot in our experiments (data not
shown). DNMT1 was consistently characterized by the
appearance of multiple bands immunoreacting with anti-
DNMT1 antibody that were absent in early passage
ERK1-GFP cells and vector controls. At present we do
not know whether these bands represent alternative
splice variants, degradation products, post-translational
modifications or some combination. Thus, increased
DNMT expression is latent in ERK transduced C10 cells
(Figure 3A), suggesting that ERK is not directly regulat-
ing DNMT expression in this model, or that compensa-
tory mechanisms prevent significant increases in DNMT
expression patterns in early passage cells.
In previous studies we have used xeroderma pigmento-
sum complementation group A (XPA) as a loading con-
trol for nuclear extracts because the expression of this
protein generally showed little change under a variety of
experimental conditions. However, we observed aFigure 3 Panel A: DNMT1, DNMT3b, XPA, and DNA-PKcs levels were i
GFP cells, relative to early passage ERK1-GFP cells and vector controls
anti-DNMT1 antibody in late passage ERK1-GFP cells. Lamin a/c was used a
independent experiments for early (white) and late (black) passage ERK1-GF
1). Values represent mean± se (n = 3). *Significantly different from vector comarked increase in the expression of XPA in late passage
ERK1-GFP cells, relative to early passage cells and vector
controls (Figure 3A). We subsequently defined the
expression of DNA-dependent protein kinase catalytic
subunit (DNA-PKcs) in late passage ERK1-GFP cells as
an additional index for DNA damage signaling which
was also increased (Figure 3A). Lamin a/c levels were
not increased under these conditions and served as load-
ing control. The combined results of three independent
experiments are illustrated in Figure 3B. The reason for
increased expression of DNA repair proteins is unclear.
One possible interpretation may relate persistent ERK
activation to genomic instability, which is a common
feature of human cancers [25]. Genomic instability
encompasses a broad array of chromosomal rearrange-
ments and DNA damage events [26] that could generate
signals leading to the regulation of repair proteins such
as XPA and DNA-PKcs. ERK regulates NADPH oxidase
activity [27], which is associated with a significant gener-
ation of oxygen free radicals [28] and chronic oxidative
stress can induce genomic instability [29]. Alternatively,
DNA-PKcs is hypothesized to play an important role in
maintaining genomic stability [30] and the increase in
DNA-PKcs may reflect effort to maintain stability in an
unstable environment.
DNMTs possess HDAC binding domains [31] and
DNMT/HDAC systems are believed to be interdepend-
ent [32]. Therefore, we surveyed whether HDAC activity
was altered under these conditions as an additional index
for altered epigenetic programming that may be directly
influenced by HDAC binding domains on DNMTs
[31,32]. HDAC activity was significantly increased in late
passage ERK1-GFP cells, relative to early passage cellsncreased in nuclear extracts prepared from late passage ERK1-
. DNMT1 consistently exhibited multiple bands immunoreacting with
s a loading control. Panel B: Graph illustrates pooled results from three
P cells, relative to vector control (referenced as fold change value of
ntrol. General methods for Western blot analysis can be found in [24].
Figure 5 5-azaC toxicity in ERK1-GFP transduced cells. Vector
control (square), early passage ERK1-GFP (circle) and late passage
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HDAC activity in late passage, but not early passage
ERK1-GFP cells, is consistent with increased DNMT
expression patterns and coupled HDAC regulation [31].
There is precedence for an ERK-DNMT-HDAC linkage
in fear conditioning [33] and we hypothesize that these
activities may also be aligned in carcinogenesis. Add-
itional studies are required to dissect the relative amount
of HDAC activity that is dependent on DNMTs in late
passage cells.
To determine if increased DNMT expression was
linked to cell fate regulation, we asked whether vector
control, early and late passage ERK1-GFP cells were dif-
ferentially sensitive to a DNMT inhibitor (5-azaC). Cells
were treated with 0.5–50 μM 5-azaC for 7 days and cell
viability was determined using a neutral red assay as
previously described [34]. Cell viability was reduced in a
dose-dependent manner by 5-azaC in late passage ERK1-
GFP cells, but not in vector controls (Figure 5).
Early passage ERK1-GFP cells displayed a small
reduction in cell viability at the highest concentrations ofFigure 4 HDAC activity in nuclear extracts from vector control,
early and late passage ERK1-GFP cells. Increased relative
fluorescence units (RFU) is an index for increased HDAC activity,
which was measured using the Fluor de Lys – Green kit (Enzo Life
Sciences, Plymouth Meeting, PA) according to manufacturer’s
directions. HDAC activity was increased in late passage ERK1-GFP
cells, relative to early passage ERK1-GFP cells and vector control.
*Significantly different from vector control. Values represent the
mean± se (n = 3). Similar results were observed in three independent
experiments.
ERK1-GFP (triangle) were maintained in media supplemented with 5-
azaC at the indicated concentrations for 7 days at which time cell
viability was measured using a neutral red assay as described [34].
Values represent the mean± se (n = 3). *Significantly different from
vector control. Similar results were observed in three independent
experiments.5-azaC (25–50 μM) employed. DNMT’s are under inves-
tigation as therapeutic targets for lung cancer [31]. Bio-
markers that can predict when DNMT inhibitors may
exhibit high efficacy could significantly aid in this effort.
Because the C10 model developed here is sensitive to
DNMT inhibitors, it may provide insight into molecular
features that may serve as biomarkers, to the extent that
such features are conserved in human cancers.
We consistently observed that late passage ERK1-GFP
cells exhibited a marked reduction in phospho-ERK
(P-ERK) levels, but not total ERK protein levels, relative to
vector controls and early passage ERK1-GFP cells
(Figure 6A). Treatment of serum starved cells (0.1% FBS)
with 10% FBS for 5 min resulted in increased P-ERK levels
in vector controls and early passage ERK1-GFP cells,
which is the expected response to serum stimulation. Lack
of P-ERK levels in late passage cells could result from either
a general lack of signal transduction leading to ERK activa-
tion or an increase in phosphatase activity. We treated late
passage ERK1-GFP cells with 1 mM sodium orthovanadate
(Na3VO4) to determine whether a broad spectrum
phosphatase inhibitor could restore P-ERK levels. P-ERK
levels were restored within minutes of Na3VO4 treatment
(Figure 6B), suggesting that the decrease in P-ERK levels
associated with late passage ERK1-GFP cells was due to
increased phosphatase activity.
Figure 6 Evidence for increased phosphatase activity in late passage ERK1-GFP cells. Panel A: Western blot analysis of P-ERK levels in
serum starved (0.1% FBS) vs 10% FBS stimulated cells. Treatment of cells with 10% FBS for 5 min results in increased P-ERK levels in vector control
and early passage ERK1-GFP cells, as expected, while late passage ERK1-GFP cells display diminished P-ERK, but not total ERK levels. Panel B:
Treatment of late passage ERK1-GFP cells with a broad spectrum phosphatase inhibitor (1 mM Na3VO4) for 5 or 60 min resulted in reappearance
of P-ERK levels, suggesting that the decrease in P-ERK levels is due to increased phosphatase activity. Similar results were observed in two
independent experiments
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Ectopic expression of ERK alone is sufficient to induce
phenotypic conversion of C10 cells and this model may
provide insight into the underlying molecular determi-
nants of this response. The window between early and
late passage ERK-transduced variants that encompasses
phenotypic conversion (approximately 15 passages) is a
reasonable time frame to enable interrogative studies to
define molecular determinants. Our expectation is that
causal molecular processes will precede the appearance
of the transformed phenotype and will be observed in
early passage cells. At present, we have characterized
changes in DNMT, DNA damage recognition and repair
proteins and phosphatase activities that are selectively
altered in late, but not early passage cells, suggesting
they are secondary to transformation. Additional studies,
perhaps with a more global screening approach, may
provide insight into those molecular processes perturbed
by ERK overexpression in early passage cells. Alterna-
tively, because DNMTs are under investigation as thera-
peutic targets for lung cancer, the C10 model may
provide insight into the molecular processes that confer
sensitivity to DNMT inhibitors and regulate their aber-
rant expression.
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